GleamWall
中文EN

KLRA Kailera Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2096997 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4.7%
Debt / equity0.00x
Current ratio21.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$84.67M$101.06M$70.87M$26.99M$19.52M$10.13M
SG&A expense$21.67M$20.31M$13.79M$13.12M$11.13M$10.33M
Operating income-$106.34M-$121.37M-$84.66M-$40.11M-$30.65M-$20.46M
Net income-$95.67M-$111.31M-$78.86M-$39.62M-$28.95M-$17.98M
EBITDA-$106.23M-$121.27M-$84.56M-$40.05M-$30.59M-$20.39M
EPS (basic)-0.74-1.09-3,650.00-39,623.00-28,947.00-17,983.00
EPS (diluted)-0.74-1.09-3,650.00-39,623.00-28,947.00-17,983.00
Weighted avg. shares (diluted)129.65M102.23M21,607111
Balance sheet
Cash & equivalents$106.54M$130.30M$111.83M$97.91M$101.37M$101.78M
Short-term investments$794.92M$786.44M$407.35M———
Current assets$919.76M$929.17M$530.32M———
PP&E, net$1.65M$1.75M$1.85M———
Total assets$1.08B$1.21B$624.76M———
Current liabilities$42.12M$83.65M$54.84M———
Total liabilities$51.06M$92.95M$64.48M———
Shareholders' equity$1.03B$1.12B-$432.09M-$297.88M-$262.58M-$235.24M
Shares outstanding129.68M129.62M29,953———
Cash flow statement
Operating cash flow-$133.67M-$77.53M-$68.31M-$29.70M-$26.23M-$18.20M
Investing cash flow$110.83M-$571.02M$22.85M$26.48M-$74.17M-$54.44M
Financing cash flow-$922,000$667.03M-$2.98M-$243,000$100.00M$0
Depreciation & amortization$101,000$101,000$101,000$63,000$62,000$63,000
Stock-based compensation$9.92M$8.34M$3.94M$4.27M$1.63M$1.52M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.